Abstract
Pregnane X receptor (PXR) is highly expressed in the liver and plays a pivotal role in xenobiotic and endobiotic metabolism. We previously reported that PXR activation by its specific mouse agonist pregnenolone 16α-carbonitrile (PCN) significantly induces liver enlargement and lipid accumulation. However, the effect of long-term PCN treatment on PXR and mouse liver is still unknown. This study aimed to explore the influence of long-term administration of PCN on mouse liver and hepatic lipid homeostasis. Male C57BL/6 mice were injected intraperitoneally with PCN (100 mg/kg once a week) for 42 weeks. Serum and liver samples were collected for biochemical and histological analysis. PXR activation was investigated by Western blot. Ultra-high-performance liquid chromatography coupled with electrospray ionization high-resolution mass spectrometry (UHPLC-ESI-HRMS)-based lipidomics analysis was performed to explore the change in different lipid categories. The results showed that long-term treatment with PCN significantly promoted hepatomegaly without hepatocyte proliferation and enlargement. Long-term treatment with PCN did not upregulate PXR target proteins in mice, and there was no significant upregulation of CYP3A11, CYP2B10, UGT1A1, MRP2, or MRP4. Lipidomics analysis showed obvious hepatic lipid accumulation in the PCN-treated mice, and the most significant change was found in triglycerides (TGs). Additionally, long-term treatment with PCN had no risk for carcinogenesis. These findings demonstrated that long-term PCN treatment induces hepatomegaly and lipid accumulation without hepatocyte proliferation or enlargement.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998;92:73–82.
Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci. 2012;33:552–8.
Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos. 2001;29:1325–31.
Bhadhprasit W, Sakuma T, Hatakeyama N, Fuwa M, Kitajima K, Nemoto N. Involvement of glucocorticoid receptor and pregnane X receptor in the regulation of mouse CYP3A44 female-predominant expression by glucocorticoid hormone. Drug Metab Dispos. 2007;35:1880–5.
Di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Asp Med. 2009;30:297–343.
Wang Y, Ong S, Chai S, Chen T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol. 2012;8:803–17.
Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology. 2017;65:1384–92.
Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos. 2001;29:1467–72.
Jiang Y, Feng D, Ma X, Fan S, Gao Y, Fu K, et al. Pregnane X receptor regulates liver size and liver cell fate by yes-associated protein activation in mice. Hepatology. 2019;69:343–58.
Shizu R, Abe T, Benoki S, Takahashi M, Kodama S, Miayata M, et al. PXR stimulates growth factor-mediated hepatocyte proliferation by cross-talk with the FOXO transcription factor. Biochem J. 2016;473:257–66.
Yao X, Jiao T, Jiang Y, Fan S, Zhao Y, Yang X, et al. PXR mediates mifepristone-induced hepatomegaly in mice. Acta Pharmacol Sin. 2021;43:146–56.
Jiao T, Yao X, Zhao Y, Zhou Y, Gao Y, Fan S, et al. Dexamethasone-induced liver enlargement is related to PXR/YAP activation and lipid accumulation but not hepatocyte proliferation. Drug Metab Dispos. 2020;48:830–9.
Zhao Y, Yao X, Jiao T, Tian J, Gao Y, Fan S, et al. Schisandrol B promotes liver enlargement via activation of PXR and YAP pathways in mice. Phytomedicine. 2021;84:153520.
Jiang Y, Yao X, Fan S, Gao Y, Zhang H, Huang M, et al. Lipidomic profiling reveals triacylglycerol accumulation in the liver during pregnane X receptor activation-induced hepatomegaly. J Pharm Biomed Anal. 2021;195:113851.
Shizu R, Ishimura M, Nobusawa S, Hosaka T, Sasaki T, Kakizaki S, et al. The influence of the long-term chemical activation of the nuclear receptor pregnane X receptor (PXR) on liver carcinogenesis in mice. Arch Toxicol. 2021;95:1089–102.
Gao Y, Fan S, Li H, Jiang Y, Yao X, Zhu S, et al. Constitutive androstane receptor induced-hepatomegaly and liver regeneration is partially via yes-associated protein activation. Acta Pharm Sin B. 2021;11:727–37.
Fan S, Gao Y, Qu A, Jiang Y, Li H, Xie G, et al. YAP-TEAD mediates PPAR alpha-induced hepatomegaly and liver regeneration in mice. Hepatology. 2022;75:74–88.
Zhang H, Wang Y, Guan L, Chen Y, Chen P, Sun J, et al. Lipidomics reveals carnitine palmitoyltransferase 1C protects cancer cells from lipotoxicity and senescence. J Pharm Anal. 2021;11:340–50.
Carthew P, Nolan BM, Edwards RE, Smith LL. The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett. 1996;106:163–9.
Kakehashi A, Kato A, Inoue M, Ishii N, Okazaki E, Wei M, et al. Cytokeratin 8/18 as a new marker of mouse liver preneoplastic lesions. Toxicol Appl Pharmacol. 2010;242:47–55.
Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19:309–23.
Abe T, Shizu R, Sasaki T, Shimizu Y, Hosaka T, Kodama S, et al. Functional interaction between pregnane X receptor and Yes-associated protein in xenobiotic-dependent liver hypertrophy and drug metabolism. J Pharmacol Exp Ther. 2019;371:590–601.
Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol. 2008;82:959–64.
Xing Y, Yan J, Niu Y. PXR: a center of transcriptional regulation in cancer. Acta Pharm Sin B 2020;10:197–206.
Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res. 2004;43:134–76.
Holčapek M, Liebisch G, Ekroos K. Lipidomic analysis. Anal Chem. 2018;90:4249–57.
Wada T, Gao J, Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab. 2009;20:273–9.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–51.
Yamaguchi K, Yang L, Mccall S, Huang J, Yu X, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366–74.
Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009;3:445–51.
Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105:1095–108.
Li LO, Ellis JM, Paich HA, Wang S, Gong N, Altshuller G, et al. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem. 2009;284:27816–26.
Brejchova K, Radner FPW, Balas L, Paluchova V, Cajka T, Chodounska H, et al. Distinct roles of adipose triglyceride lipase and hormone-sensitive lipase in the catabolism of triacylglycerol estolides. Proc Natl Acad Sci USA. 2021; 118.
Van Der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017;1859:1558–72.
Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006;3:321–31.
Kim HY, Huang BX, Spector AA. Phosphatidylserine in the brain: metabolism and function. Prog Lipid Res. 2014;56:1–18.
Leventis PA, Grinstein S. The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys. 2010;39:407–27.
Kotiya D, Jaiswal B, Ghose S, Kaul R, Datta K, Tyagi RK. Role of PXR in hepatic cancer: its influences on liver detoxification capacity and cancer progression. PLoS One. 2016;11:e0164087.
Ouyang N, Ke S, Eagleton N, Xie Y, Chen G, Laffins B, et al. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Cancer. 2010;102:1753–61.
Niu Y, Wang Z, Huang H, Zhong S, Cai W, Xie Y, et al. Activated pregnane X receptor inhibits cervical cancer cell proliferation and tumorigenicity by inducing G2/M cell-cycle arrest. Cancer Lett. 2014;347:88–97.
Acknowledgements
The work was supported by the National Natural Science Foundation of China [Grant number: 82025034, 81973392], the National Key Research and Development Program (Grant number: 2017YFE0109900), the Shenzhen Science and Technology Program (KQTD20190929174023858), the 111 project (Grant number: B16047), and the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [Grant number: 2017BT01Y093].
Author information
Authors and Affiliations
Contributions
MH and HCB participated in research design. YFZ, JY, SCF, YG, and YMJ performed experiments. YFZ, YG, and HCB wrote or revised the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Zhang, Yf., Gao, Y., Yang, J. et al. Long-term treatment with the mPXR agonist PCN promotes hepatomegaly and lipid accumulation without hepatocyte proliferation in mice. Acta Pharmacol Sin 44, 169–177 (2023). https://doi.org/10.1038/s41401-022-00925-3
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41401-022-00925-3
Keywords
This article is cited by
-
Adverse outcome pathway for pregnane X receptor-induced hypercholesterolemia
Archives of Toxicology (2023)
